PRIME II ‘extremely reassuring’ on radiotherapy omission in older women with early breast cancer
The 10-year data from the PRIME II trial suggest that radiotherapy after breast-conserving surgery can be omitted for women aged 65 years or older with low-risk, hormone receptor-positive early breast cancer.
iNTEGRATE fails to demonstrate significant cGVHD benefit for ibrutinib–prednisone regimen
Combining ibrutinib and prednisone for the treatment of new-onset chronic graft-versus-host disease after allogeneic haematopoietic cell transplantation does not improve patient response compared with prednisone alone, show phase 3 trial findings published in the Journal of Clinical Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Maintenance darolutamide shows promise in metastatic CRPC
Phase 2 data point to the potential of switch maintenance with darolutamide in men with metastatic castration-resistant prostate cancer that has not progressed after taxane therapy.
Sotorasib demonstrates potential for KRAS-mutated pancreatic cancer
The KRAS G12C inhibitor sotorasib has shown “promising anticancer activity” in a phase 1/2 trial of patients with heavily pretreated, metastatic pancreatic cancer harbouring the target mutation, researchers report in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
CT brain cancer risk quantified for children and young adults
The European EPI-CT study has confirmed there is a linear dose–response relationship between radiation exposure during computed tomography imaging and the risk of malignant brain tumours, in children and young adults.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Antibody testing may identify cancer patients at increased risk of COVID-19 breakthrough infections
A Canadian population-based study has confirmed that people with cancer have an increased risk of breakthrough COVID-19 infection after vaccination, while UK research points to the feasibility of SARS-CoV-2 antibody testing to identify those with the lowest level of vaccine-derived protection.
First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer
Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.
Minimal access breast surgery ‘valid’ option for early breast cancer
Minimal access breast surgery offers comparable long-term outcomes to conventional surgery for women with stage 0–III breast cancer, show the results of a propensity-matched, retrospective cohort study.
Meta-analysis reveals high risk for cutaneous AEs with PI3K inhibitors
The use of PI3K inhibitors for the treatment of cancer is associated with a high risk for developing cutaneous adverse events, suggests a meta-analysis published in JAMA Oncology.
High IL-6, CRP may predict increased frailty after breast cancer chemotherapy
Clinically fit older women with early breast cancer are more likely to experience chemotherapy-induced decline in frailty if they have high pretreatment levels of IL-6 and CRP, research shows.
